Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117681 | 0.97 | CA12 (0.44) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL12578307 | 0.91 | PDK2 (0.45) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL2909678 | 0.89 | FFAR1 (0.49) | FFAR1CD274MCL1 | |
| SCHEMBL10203769 | 0.85 | CA12 (0.44) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL10203757 | 0.84 | CA1 (0.47) | CA12CA1CA2CA9CD274 | |
| SCHEMBL13139653 | 0.84 | CD274 (0.46) | FFAR1CD274 | |
| SCHEMBL10203750 | 0.84 | CA1 (0.46) | CA12CA1CA2CA9CD274 | |
| SCHEMBL13117675 | 0.83 | FFAR1 (0.51) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL12578389 | 0.82 | FFAR1 (0.48) | FFAR1CD274 | |
| SCHEMBL10264664 | 0.82 | PDK2 (0.45) | CA12CA1CA2CA9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | CA12 4685/4885CA1 4452/4885CA2 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.